ASTRAZENECA ONCOLOGY EDUCATION. Invitation Nordic - Baltic Masterclass. BRCA tumor testing

Størrelse: px

Starte visningen fra side:

Download "ASTRAZENECA ONCOLOGY EDUCATION. Invitation Nordic - Baltic Masterclass. BRCA tumor testing"

Grethe Beck
7 år siden
Visninger:

1 ASTRAZENECA ONCOLOGY EDUCATION Invitation Nordic - Baltic Masterclass BRCA tumor testing February, 28 th 2017

2 In co-operation with: Estrid Høgdall, Professor, Dr. Sc., Ph.d., Head of Molecular Unit, Herlev Hospital, University of Copenhagen, AstraZeneca arranges a Nordic Baltic Master Class Course Summary: The course will focus on BRCA tumor testing in ovarian and breast cancer Topics covered will focus on BRCA1 & BRCA2 mutations Which patient s should we test? How to test BRCA? Who is going to prescribe the BRCA test? How should the genetic counselling process look like? What could become the future (somatic & germline testing)? Date and time: Tuesday the 28th February 2017 at 9:30 to 16:30 Meeting place: Scandic Copenhagen, Vester Søgade 6, 1601 Copenhagen V Participants: Healthcare professionals working within oncology, pathology, genetics and biochemistry Signing up for the course: Before 15th February via to mette.sorensen@astrazeneca.com Please state country, workplace, your name and telephone number. Numbers of seats limited. Final registration will be confirmed by AstraZeneca AstraZeneca cannot reimburse your travel costs

3 Program Tuesday the 28 th February :30-10:00 Coffee Welcome and introduction Why focus on BRCA1 and BRCA2 - How far are we? 10:00-10:15 Estrid Høgdall, Professor, Dr. Sc., Ph.d., Head of Molecular Unit, Herlev Hospital, University of Copenhagen Hereditary breast and ovarian cancer - Consequences for the patient and their family 10:15-10:45 Anne-Marie Gerdes, Professor, Ph.d., Head of Genetic Clinic, Review of Danish guidelines in BRCA mutated Patients in breast cancer 10:45-11:15 Bent Ejlertsen, Prof. Ph.d., Head of DBCG, Dept. Of Oncology, Norwegian germline BRCA testing up-front at diagnosis on patients with breast cancer 11:15-11:45 Lovise Mæhle, MD, Ph.d. Head of Heriditary cancer unit, Oslo University Hospital Lunch 11:45 12:45 Review of Danish guidelines in BRCA mutated Patients in breast cancer 12:45-13:15 Claus Høgdall, Professor Dr. Sc., Gynaecologic Clinic, Why do we need tumor testing in ovarian cancer and who should be tested Mansoor Mirza, Chief Oncologist, Dept. of Oncology, KIU Women with reproductive cancers Patient Association perspectives 13:45-14:15 Birthe Lemley, President of KIU (Kræft I Underlivet) Coffee 14:15 14:30

4 How do we test in blood? What are the technical issues? 14:30-15:00 Mads Thomassen, Associate Professor, Molecular biologist, Ph.d., Human Genetics, Department of Clinical Research, Odense University Hospital How do we test in tissue? What are the technical issues? 15:00-15:30 Tim Svenstrup Poulsen, Molecular Biologist, Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen Classification of variants and implications for testing tumor tissue for germline mutations 15:30 16:00 Thomas Hansen Head Biochemist, Ph.d., Center of Genomic Medicine, Wrap-up and future demands for testing 16:00 16:30 Estrid Høgdall, Professor,Dr.,Sc.,Ph.d., Head of Molecular Unit, Herlev Hospital

5 Yours sincerely Estrid Høgdall Professor, Dr., Sc., Ph.d. Head of Molecular Unit Herlev Hospital Per Barfod Nordic Diagnostic Manager Mette Sørensen Strategic Account Manager Ulla Jensen National Oncology Lead DK Det er med AstraZenecas invitation og den relaterede økonomiske støtte ikke intentionen at fremkalde eller begunstige ordination af AstraZeneca lægemidler eller enhver anden uretmæssig handling som begunstiger AstraZeneca. Hvis du deltager i foranstaltninger eller afgørelser, der berører et AstraZeneca produkt eller brug (f.eks. registrering af et lægemiddel eller tilskud, udbud) inden for en rimelig frist efter at være blevet valgt som deltager / delegeret, bør du overveje ikke at deltage i disse foranstaltninger eller afgørelser, for at undgå enhver opfattelse af utilbørlig indflydelse. Iflg. Reklamebekendtgørelsen må kun sundhedspersoner deltage i AstraZenecas efteruddannelsesarrangementer. Ved sundhedspersoner forstås læger, tandlæger, dyrlæger, farmaceuter, sygeplejersker, veterinærsygeplejersker, farmakonomer, jordemødre, bioanalytikere, kliniske diætister, radiografer, social- og sundhedsassistenter og studerende inden for disse fag. Når du tilmelder dig dette møde, indsamler AstraZeneca dine personoplysninger (fx navn, ). Formålet med indsamlingen er at administrere og bekræfte din deltagelse i mødet. AstraZeneca opbevarer dine oplysninger i en periode på 6 måneder fra den dato, hvor mødet finder sted. Ved at kontakte os skriftligt, kan du anmode om kopi af de oplysninger, som AstraZeneca har om dig, og/eller anmode om korrektion af dine oplysninger. Ved at sende os dine oplysninger, accepterer du behandlingen af dine personoplysninger som beskrevet. Arrangementet vil blive anmeldt til Etisk Nævn for Lægemiddelindustrien (ENLI), inden arrangementets afholdelse, og arrangementet er i sin eksisterende form og indhold forhåndsgodkendt af ENLI. ATLAS APPROVAL ID Number ,011,, Arne Jacobsens Allé 13, DK-2300 Copenhagen S.

Relaterede dokumenter

Hvad er en biobank? Hvad skal vi forvente af regionernes biobanker? Hvorfor har og får de en rolle?

Hvad er en biobank? Hvad skal vi forvente af regionernes biobanker? Hvorfor har og får de en rolle? Estrid Høgdall Regionernes Biobank Sekretariat Patologiafdelingen, Herlev Hospital Biobank har en rolle